Saturday, July 16, 2016 11:08:20 AM
ALSO JUNO MENTIONED
Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO
William Meyers
Follow (1,085 followers)
Long only, tech, biotech, research analyst
Summary
•Acute Myeloid Leukemia is very difficult to treat successfully.
•Seattle Genetics SGN-CD33A started a Phase 3 trial.
•GlycoMimetics GMI-1271 started Phase 2 trial.
•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.
http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM